Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
10.1191/026921699667559279 83 MoallemN
& Hui, L
After screening of titles and abstract, and removal of the results overlapping with the previous search, 16 additional papers were selected as relevant for the review
(Switzerland) Altimmune (US) Glenmark Pharmaceuticals Ltd (India) Biocon (India) Teva Pharmaceuticals (Israel) MARKET SCOPE WHAT IS IN IT FOR YOU: GLP-1 Agonists Market REPORT CONTENT GUIDE DELIVERED CUSTOMIZATIONS We have successfully delivered the following deep-dive customizations: RECENT DEVELOPMENTS September 2025 : Novo Nordisk (Denmark) received EU approval for its oral GLP-1 receptor agonist drug, Rybelsus, to reduce cardiovascular death, heart attack, and stroke
01585-5/asset/19c5e1a6-3ebc-453e-87c3-a11a7b2d6a64/main.assets/gr1.gif)
US$ 27.65
US$ 24.30
US$ 22.87
US$ 29.76
US$ 22.97
US$ 26.04
